Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.

[1]  D. Roth,et al.  The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. , 2011, Ophthalmology.

[2]  Quan Dong Nguyen,et al.  Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. , 2011, Ophthalmology.

[3]  M. Blumenkranz,et al.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. , 2010, Ophthalmology.

[4]  Sarah Gray,et al.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[5]  Tien Yin Wong,et al.  The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. , 2010, Ophthalmology.

[6]  Ingrid U Scott,et al.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. , 2009, Archives of ophthalmology.

[7]  Ronald Klein,et al.  The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. , 2008, Archives of ophthalmology.

[8]  P. Rosenfeld,et al.  Predicted biological activity of intravitreal VEGF Trap , 2008, British Journal of Ophthalmology.

[9]  Sharon D. Solomon,et al.  Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Mitchell,et al.  Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. , 1996, Archives of ophthalmology.

[12]  David J. Wilson,et al.  Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. , 1995, Ophthalmology.

[13]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[14]  M. Zimmerman,et al.  Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. , 1994, American journal of ophthalmology.

[15]  A. Patz,et al.  Retinal branch vein occlusion. , 1978, Survey of ophthalmology.

[16]  Scott Carver,et al.  Cytokine traps: multi-component, high-affinity blockers of cytokine action , 2003, Nature Medicine.

[17]  Ditte J. Hess,et al.  A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. , 1995, Ophthalmology.